A Phase 2 interventional study of AGN-241751 and Placebo in Depressive Disorder, Major, sponsored by Syndeio Biosciences, Inc. Completed at 25 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-04-27.
Sponsored by Syndeio Biosciences, Inc · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,500 studies in Depressive Disorder, Major with a site in United States — 215 open to participants now, 259 under way, 27 of them phase 3. Depressive Disorder, Major · United States.
Among the 1,500 studies in Depressive Disorder, Major with a site in United States, this one is the 288th largest by enrollment of the 1,323 interventional ones that give a count, is one of 50 that started in 2018, is one of 271 in phase 2, and was the 944th registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →215 of the 1,500 studies in Depressive Disorder, Major with a site in United States are open now. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 22–60
Baylor College of Medicine · Sites in United States
Ages 18–64
Ohio State University · Sites in United States
Ages 21–65
Florida State University · Sites in United States
Ages 18–55 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,500 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 135 · Phase 2 325 · Phase 3 262 · Phase 4 189
First in 1979; this study’s year is marked. 50 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 251 is above the median of 80 across 2,534 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 70 across the 1,323 interventional studies, 100 across the 171 observational. Of the 1,156 that completed or were terminated, 584 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
484 of 1,500 have an industry lead sponsor. The 10 most frequent:
Syndeio Biosciences, Inc is the lead sponsor of 6 studies on the registry; 2 are open to participants now.
Syndeio Biosciences, Inc has 5 studies filed under Depressive Disorder, Major — fewer than ten, so there is no comparison to draw.
99 of the studies in Depressive Disorder, Major with a site in United States that are under way reach primary completion within a year, 10 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06559306Phase 3Janssen Research & Development, LLCPhase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms | 2026-12-30 |
| NCT06922110Phase 3Xenon Pharmaceuticals Inc.An Open-Label Study of Azetukalner in Major Depressive Disorder | 2027-01 |
| NCT04041479Phase 3Weill Medical College of Cornell UniversityBiomarker-guided rTMS for Treatment Resistant Depression | 2027-04 |
| NCT05850689Phase 3Intra-Cellular Therapies, Inc.Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder | 2027-04-05 |
| NCT07076407Phase 3Xenon Pharmaceuticals Inc.A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) | 2027-05 |
Add all 99 to your calendar (.ics) → With an account.
Among the 1,500 studies in Depressive Disorder, Major with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy at 1 day post initial oral dose of zelquistinel (AGN-241751) compared with placebo in participants with Major Depressive Disorder (MDD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Psychiatric and Treatment-Related Criteria
Other Medical Criteria
Other Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
AGN-241751 Dose 1 administered as 1 tablet taken orally every day
Drug: AGN-241751
AGN-241751 Dose 2 administered as 1 tablet taken orally every day
Drug: AGN-241751
AGN-241751 Dose 3 administered as 1 tablet taken orally every day
Drug: AGN-241751
AGN-241751 Dose 4 administered as 1 tablet taken orally every day
Drug: AGN-241751
Placebo administered as 1 tablet taken orally every day
Drug: Placebo
AGN-241751 administered orally as a single tablet
Placebo administered orally as a single tablet
Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
The MADRS is a clinician-rated scale to assess depressive symptomatology during the preceding week. Participants are rated on 10 items (feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty concentrating, and lack of interest) each on a 7-point scale from 0 (no symptoms) to 6 (symptoms of maximum severity). The total score ranges from 0 to 60 with a higher score indicating more depression. A negative change score indicates improvement.
Time frame: Baseline to Day 1
Change From Baseline in MADRS Total Score at Week 3
The MADRS is a clinician-rated scale to assess depressive symptomatology during the preceding week. Participants are rated on 10 items (feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty concentrating, and lack of interest) each on a 7-point scale from 0 (no symptoms) to 6 (symptoms of maximum severity). The total score ranges from 0 to 60 with a higher score indicating more depression. A negative change score indicates improvement.
Time frame: Baseline to Week 3
| Milestone | AGN-241751 Dose 1 | AGN-241751 Dose 2 | AGN-241751 Dose 3 | AGN-241751 Dose 4 | Placebo |
|---|---|---|---|---|---|
| Started | 48 | 50 | 52 | 50 | 51 |
| Completed | 48 | 46 | 46 | 46 | 46 |
| Not completed | 0 | 4 | 6 | 4 | 5 |
| Withdrew: Lost to follow-up | 0 | 3 | 1 | 3 | 3 |
| Withdrew: Withdrawal by subject | 0 | 1 | 2 | 1 | 1 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 1 | 0 | 1 |
| Withdrew: Noncompliance with study drug | 0 | 0 | 1 | 0 | 0 |
The MADRS is a clinician-rated scale to assess depressive symptomatology during the preceding week. Participants are rated on 10 items (feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty concentrating, and lack of interest) each on a 7-point scale from 0 (no symptoms) to 6 (symptoms of maximum severity). The total score ranges from 0 to 60 with a higher score indicating more depression. A negative change score indicates improvement.
| score on a scale | AGN-241751 Dose 1 | AGN-241751 Dose 2 | AGN-241751 Dose 3 | AGN-241751 Dose 4 | Placebo |
|---|---|---|---|---|---|
| Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score | -8.6 ± 1.21 | -8.0 ± 1.19 | -9.5 ± 1.18 | -10.6 ± 1.18 | -7.7 ± 1.18 |
The MADRS is a clinician-rated scale to assess depressive symptomatology during the preceding week. Participants are rated on 10 items (feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty concentrating, and lack of interest) each on a 7-point scale from 0 (no symptoms) to 6 (symptoms of maximum severity). The total score ranges from 0 to 60 with a higher score indicating more depression. A negative change score indicates improvement.
| score on a scale | AGN-241751 Dose 1 | AGN-241751 Dose 2 | AGN-241751 Dose 3 | AGN-241751 Dose 4 | Placebo |
|---|---|---|---|---|---|
| Change From Baseline in MADRS Total Score at Week 3 | -11.5 ± 1.56 | -12.5 ± 1.54 | -14.1 ± 1.55 | -13.5 ± 1.54 | -13.6 ± 1.54 |
Collected over 4 weeks. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AGN-241751 Dose 1 | 0/48 (0%) | 0/48 (0%) | 17/48 (35.4%) |
| AGN-241751 Dose 2 | 0/50 (0%) | 0/50 (0%) | 18/50 (36%) |
| AGN-241751 Dose 3 | 0/52 (0%) | 0/52 (0%) | 12/52 (23.1%) |
| AGN-241751 Dose 4 | 0/50 (0%) | 0/50 (0%) | 19/50 (38%) |
| Placebo | 0/51 (0%) | 0/51 (0%) | 16/51 (31.4%) |
| Event | AGN-241751 Dose 1 | AGN-241751 Dose 2 | AGN-241751 Dose 3 | AGN-241751 Dose 4 | Placebo |
|---|---|---|---|---|---|
| InsomniaNervous system disorders | 0/48 | 5/50 | 0/52 | 1/50 | 1/51 |
| HeadacheNervous system disorders | 3/48 | 3/50 | 3/52 | 2/50 | 4/51 |
| DizzinessNervous system disorders | 2/48 | 0/50 | 3/52 | 3/50 | 2/51 |
| NauseaGastrointestinal disorders | 1/48 | 3/50 | 2/52 | 1/50 | 2/51 |
| Dry MouthGastrointestinal disorders | 0/48 | 1/50 | 0/52 | 3/50 | 1/51 |
| AnxietyPsychiatric disorders | 0/48 | 1/50 | 3/52 | 1/50 | 0/51 |
| SomnolenceNervous system disorders | 2/48 | 1/50 | 0/52 | 1/50 | 2/51 |
| SedationNervous system disorders | 2/48 | 0/50 | 0/52 | 1/50 | 2/51 |
| Upper Respiratory Tract InfectionInfections and infestations | 2/48 | 1/50 | 1/52 | 2/50 | 1/51 |
| DiarrheaGastrointestinal disorders | 2/48 | 0/50 | 0/52 | 1/50 | 0/51 |
| Age, Continuous(years) | AGN-241751 Dose 1 | AGN-241751 Dose 2 | AGN-241751 Dose 3 | AGN-241751 Dose 4 | Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 41.8 ± 14.02 | 41.8 ± 13.53 | 42.2 ± 14.23 | 42.9 ± 13.48 | 40.0 ± 14.49 | 41.7 ± 13.88 |
| Sex: Female, Male(Participants) | AGN-241751 Dose 1 | AGN-241751 Dose 2 | AGN-241751 Dose 3 | AGN-241751 Dose 4 | Placebo | Total |
|---|---|---|---|---|---|---|
| Female | 33 | 15 | 16 | 20 | 30 | 114 |
| Male | 15 | 35 | 36 | 30 | 21 | 137 |
| Race (NIH/OMB)(Participants) | AGN-241751 Dose 1 | AGN-241751 Dose 2 | AGN-241751 Dose 3 | AGN-241751 Dose 4 | Placebo | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 1 | 1 |
| Asian | 3 | 1 | 1 | 2 | 1 | 8 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 0 | 0 | 1 |
| Black or African American | 18 | 24 | 22 | 15 | 20 | 99 |
| White | 24 | 24 | 28 | 32 | 27 | 135 |
| More than one race | 1 | 1 | 1 | 0 | 2 | 5 |
| Unknown or Not Reported | 1 | 0 | 0 | 1 | 0 | 2 |
| Region of Enrollment(participants) | AGN-241751 Dose 1 | AGN-241751 Dose 2 | AGN-241751 Dose 3 | AGN-241751 Dose 4 | Placebo | Total |
|---|---|---|---|---|---|---|
| United States | 48 | 50 | 52 | 50 | 51 | 251 |
| Current antidepressant usage(Participants) | AGN-241751 Dose 1 | AGN-241751 Dose 2 | AGN-241751 Dose 3 | AGN-241751 Dose 4 | Placebo | Total |
|---|---|---|---|---|---|---|
| Count of participants | 7 | 13 | 13 | 13 | 11 | 57 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — This is a phase 2 dose finding proof of concept study therefore data will not be shared.
Ran from Jun 2018 to primary completion in Jul 2019, 13 months.
Results were first posted in Aug 2022, 3 years after primary completion. A results delay was requested in Jul 2020.
Of 96 industry-sponsored phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 23. This study's 13 months is below that.
Counting every sponsor, half of 195 studies reached it within 22 months; a quarter within 14 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zelquistinel
Syndeio Biosciences, Inc